Company profile: Telesis Bio
1.1 - Company Overview
Company description
- Provider of automated synthetic biology tools, including the BioXp benchtop platform to generate synthetic DNA and mRNA, and kits for mRNA synthesis, DNA cloning (up to 24 kb), error-corrected gene synthesis (up to 1.8 kb), library creation with site-saturation variants (NNN/NNK/IUPAC), and cell-free DNA amplification for transfection-scale output in under a day.
Products and services
- BioXp Gene Synthesis Kit: Supplies reagents for error-corrected, de novo synthesis of synthetic genes up to 1.8 kb, supporting accurate gene creation for synthetic biology workflows
- BioXp mRNA Synthesis Kit: Executes 1-step or 2-step synthesis of capped and tailed synthetic mRNA from digital sequences or intermediate DNA templates for synthetic mRNA generation
- BioXp Platform: Fully automated benchtop system orchestrating synthetic biology workflows, enabling generation of synthetic DNA and mRNA, empowering researchers with tools to secure design, code, and create
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Telesis Bio
Emulate
HQ: United States
Website
- Description: Provider of advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emulate company profile →
ChromoTek
HQ: Germany
Website
- Description: Provider of immunologic research and detection reagents and tools for proteomics and cell biology, offering Nanobody-based Nano-Traps for immunoprecipitation; Chromobodies for real-time, live-cell imaging; Nano-Secondary reagents for higher-resolution imaging with minimal label displacement; Nano-Boosters & Nano-Labels for microscopy; Nano-Caps for one-step protein purification; and Nano-CaptureLigands for site-directed antibody immobilization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ChromoTek company profile →
Fluidic
HQ: United Kingdom
Website
- Description: Provider of tools for protein characterization, designing, developing and manufacturing instruments based on Microfluidic Diffusional Sizing (MDS) to analyze protein interactions in their native conditions without immobilization, delivering data on affinity, size and concentration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluidic company profile →
Zedira
HQ: Germany
Website
- Description: Provider of transglutaminase-focused biotech solutions, including specialty reagents for R&D and diagnostics; small-molecule drug candidates such as ZED1227 for celiac disease; fee-for-service transglutaminase activity measurement; recombinant microbial transglutaminase (Andracon) for ADC production; diagnostic antigens (TG2, TG3, TG6, DGPs); and an Anti-TG6 ELISA kit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zedira company profile →
SAMDI Tech
HQ: United States
Website
- Description: Provider of contract assay services offering label-free biochemical assays for drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SAMDI Tech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Telesis Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Telesis Bio
2.2 - Growth funds investing in similar companies to Telesis Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Telesis Bio
4.2 - Public trading comparable groups for Telesis Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →